dc.contributor.author |
Mahfoud Z. |
dc.contributor.author |
Kassak K. |
dc.contributor.author |
Kreidieh K. |
dc.contributor.author |
Shamra S. |
dc.contributor.author |
Ramia S. |
dc.contributor.editor |
|
dc.date |
2010 |
dc.date.accessioned |
2017-10-18T13:38:21Z |
dc.date.available |
2017-10-18T13:38:21Z |
dc.date.issued |
2010 |
dc.identifier |
10.1186/1743-422X-7-96 |
dc.identifier.isbn |
|
dc.identifier.issn |
|
dc.identifier.uri |
http://hdl.handle.net/10938/20715 |
dc.description.abstract |
Background: The aim of this study is to determine the prevalence of anti-HCV among injecting drug users (IDUs) in Lebanon, to establish the current prevalence of HCV genotypes in this population and to determine whether demographic characteristics and behavioral variables differ between participants who were HCV-RNA positive and those who were HCV-RNA negative or between the different genotypes. Participants were recruited using respondent-driven sampling method. The blood samples were collected as dried blood spots and then eluted to be tested for HCV, HBV and HIV by ELISA. Anti-HCV positive samples were subjected to RNA extraction followed by qualitative detection and genotyping. Results: Among 106 IDUs, 56 (52.8percent) were anti-HCV-positive. The two groups did not differ in terms of age, marital status, and nationality. As for the behavioral variable, there was a trend of increased risky behaviors among the HCV-RNA positive group as compared to the HCV-RNA negative group but none of the variables reached statistical significance. Half (50percent) of the 56 anti-HCV-positive were HCV-RNA positive. Genotype 3 was the predominant one (57.1percent) followed by genotype 1 (21percent) and genotype 4 (18percent). Conclusions: The predominance of genotype 3 seems to be the predominant genotype among IDUs in Lebanon, a situation similar to that among IDUs in Western Europe. This study provides a base-line against possible future radical epidemiological variant that might occur in IDUs. © 2010 Mahfoud et al; licensee BioMed Central Ltd. |
dc.format.extent |
|
dc.language |
English |
dc.publisher |
LONDON |
dc.relation.ispartof |
Publication Name: Virology Journal; Publication Year: 2010; Volume: 7; |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon |
dc.type |
Article |
dc.contributor.affiliation |
Mahfoud, Z., Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Kassak, K., Department of Health Management and Policy, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Kreidieh, K., Department Medical Laboratory Sciences, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Shamra, S., Department Medical Laboratory Sciences, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Ramia, S., Department Medical Laboratory Sciences, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon |
dc.contributor.authorAddress |
Ramia, S.; Department Medical Laboratory Sciences, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon; email: sramia@live.com |
dc.contributor.authorCorporate |
University: American University of Beirut; Faculty: Faculty of Health Sciences; Department: Medical Laboratory Sciences Program; |
dc.contributor.authorDepartment |
Medical Laboratory Sciences Program |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
sramia@live.com |
dc.contributor.faculty |
Faculty of Health Sciences |
dc.contributor.authorInitials |
Mahfoud, Z |
dc.contributor.authorInitials |
Kassak, K |
dc.contributor.authorInitials |
Kreidieh, K |
dc.contributor.authorInitials |
Shamra, S |
dc.contributor.authorInitials |
Ramia, S |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Ramia, S (reprint author), Amer Univ Beirut, Fac Hlth Sci, Dept Med Lab Sci, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut |
dc.description.cited |
Alzahrani AJ, 2008, J MED VIROL, V80, P603, DOI 10.1002-jmv.21075; deLamballerie X, 1997, J GEN VIROL, V78, P45; Freeman AJ, 2000, MED J AUSTRALIA, V172, P588; Goldberg D, 2001, SCAND J INFECT DIS, V33, P457; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525-sp.1997.44.2.03x0221m; Kurbanov F, 2003, J MED VIROL, V69, P367, DOI 10.1002-jmv.10298; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056-NEJM200107053450107; Lucidarme D, 2007, GASTROEN CLIN BIOL, V31, P480, DOI 10.1016-S0399-8320(07)89415-2; Mathei C, 2001, J INFECT DIS, V184, P659, DOI 10.1086-322795; Mathei C, 2005, EUR J CLIN MICROBIOL, V24, P514, DOI 10.1007-s10096-005-1376-9; Micalessi MI, 2008, J MED VIROL, V80, P640, DOI 10.1002-jmv.21145; Parker SP, 1999, J CLIN PATHOL, V52, P633; PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607; Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016-S0140-6736(03)15109-4; Pybus Oliver G., 2005, Infection Genetics and Evolution, V5, P131, DOI 10.1016-j.meegid.2004.08.001; Sharara AI, 2007, EPIDEMIOL INFECT, V135, P427, DOI 10.1017-S0950268806006911; SILINI E, 1995, J HEPATOL, V22, P691, DOI 10.1016-0168-8278(95)80225-8; SIMMONDS P, 1998, HEPATITIS C VIRUS; Taylor A, 2000, J INFECTION, V40, P176, DOI 10.1053-jinf.2000.0647; Tokita H, 1996, J GEN VIROL, V77, P293, DOI 10.1099-0022-1317-77-2-293; TOKITA H, 1995, J GEN VIROL, V76, P2329, DOI 10.1099-0022-1317-76-9-2329; Zamani S, 2007, INT J DRUG POLICY, V18, P359, DOI 10.1016-j.drugpo.2007.02.007 |
dc.description.citedCount |
13 |
dc.description.citedTotWOSCount |
12 |
dc.description.citedWOSCount |
11 |
dc.format.extentCount |
1 |
dc.identifier.articleNo |
96 |
dc.identifier.coden |
|
dc.identifier.pubmedID |
20465784 |
dc.identifier.scopusID |
77952032782 |
dc.identifier.url |
|
dc.publisher.address |
236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Virol. J. |
dc.relation.ispartOfIssue |
|
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Virology Journal |
dc.relation.ispartofPubTitleAbbr |
Virol. J. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
7 |
dc.source.ID |
WOS:000279550700001 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
Hepatitis C Antibodies |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
aged |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
blood sampling |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
dried blood spot testing |
dc.subject.otherIndex |
drug use |
dc.subject.otherIndex |
enzyme linked immunosorbent assay |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
genotype |
dc.subject.otherIndex |
genotyping technique |
dc.subject.otherIndex |
Hepatitis B virus |
dc.subject.otherIndex |
Hepatitis C virus |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
Human immunodeficiency virus |
dc.subject.otherIndex |
human tissue |
dc.subject.otherIndex |
Lebanon |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
male |
dc.subject.otherIndex |
marriage |
dc.subject.otherIndex |
prevalence |
dc.subject.otherIndex |
qualitative analysis |
dc.subject.otherIndex |
RNA extraction |
dc.subject.otherIndex |
statistical significance |
dc.subject.otherIndex |
Western Europe |
dc.subject.otherIndex |
blood |
dc.subject.otherIndex |
classification |
dc.subject.otherIndex |
drug use |
dc.subject.otherIndex |
genetics |
dc.subject.otherIndex |
hepatitis C |
dc.subject.otherIndex |
isolation and purification |
dc.subject.otherIndex |
Lebanon |
dc.subject.otherIndex |
middle aged |
dc.subject.otherIndex |
virology |
dc.subject.otherIndex |
Hepatitis B virus |
dc.subject.otherIndex |
Hepatitis C virus |
dc.subject.otherIndex |
hepatitis C antibody |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Drug Users |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Genotype |
dc.subject.otherIndex |
Hepacivirus |
dc.subject.otherIndex |
Hepatitis C |
dc.subject.otherIndex |
Hepatitis C Antibodies |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Lebanon |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Young Adult |
dc.subject.otherKeywordPlus |
MOLECULAR EPIDEMIOLOGY |
dc.subject.otherKeywordPlus |
GENETIC GROUPS |
dc.subject.otherKeywordPlus |
INFECTION |
dc.subject.otherKeywordPlus |
PREVALENCE |
dc.subject.otherKeywordPlus |
HCV |
dc.subject.otherKeywordPlus |
VARIANTS |
dc.subject.otherKeywordPlus |
GLASGOW |
dc.subject.otherKeywordPlus |
BELGIUM |
dc.subject.otherWOS |
Virology |